Scholarlink

Background <p>An induction regimen, followed by autologous stem cell transplantation (ASCT) and subsequent maintenance therapy, is a standard practice for patients with newly diagnosed multiple myeloma (MM) who are eligible for transplantation. The effectiveness of short-term consolidation regimens following ASCT remains ambiguous and is not yet incorporated into MM guidelines.</p> Methods <p>This study consecutively enrolled patients with MM who had a bortezomib-based induction regimen prior to ASCT. A total of one hundred twelve patients who achieved at least a partial response at two months post-autologous stem cell transplantation were studied [median age: 59 (30–74) years; male/female ratio: 60/52].</p> Results <p>Twenty-five patients did not undergo any consolidation, whereas eighty-seven patients got a median of 2 cycles (range: 1–6) of cyclophosphamide-bortezomib-dexamethasone (CyBorD) for Bortezomib-Lenalidomide-Dexamethasone (VRD) consolidation following ASCT. Progression-free survival (PFS) in the overall trial cohort was longer in patients receiving consolidation therapy (57 months versus 44 months, <i>p</i> = 0.06). Among patients exhibiting a very good partial response (VGPR) or partial response (PR) to ASCT, PFS was markedly prolonged in those who underwent consolidation cycles compared to those who did not (57 vs. 12 months; <i>p</i> = 0.04). Conversely, in the stringent complete remission (sCR) or complete remission (CR) cohort, PFS did not differ between patients who received consolidation cycles and those who did not. The analysis revealed no statistically significant differences in overall survival (OS) between the two answer category groups (<i>p</i> &gt; 0.05). The PFS (<i>p</i> &gt; 0.05) and incidence of severe toxicity (<i>p</i> &gt; 0.05) were comparable for patients receiving CyBorD and VRD consolidation regimens.</p> Conclusions <p>Our study demonstrated that consolidation therapy is safe regarding its adverse effect profile, and that its beneficial impact on PFS in first-line treatment is particularly evident in patients exhibiting VGPR and PR to ASCT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Is Consolidation Therapy Effective in Multiple Myeloma Patients after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Single Center Real-Life Data with Cyclophosphamide-Bortezomib-Dexamethasone or Bortezomib-Lenalidomide-Dexamethasone?

  • 期刊论文

  • 发表日期：

    2025年5月28日

查看全文
  • Şeyma Yıldız,
  • Asil Demirezen,
  • Zeynep Arzu Yeğin,
  • Münci Yağcı,
  • Zübeyde Nur Özkurt

摘要

Background

An induction regimen, followed by autologous stem cell transplantation (ASCT) and subsequent maintenance therapy, is a standard practice for patients with newly diagnosed multiple myeloma (MM) who are eligible for transplantation. The effectiveness of short-term consolidation regimens following ASCT remains ambiguous and is not yet incorporated into MM guidelines.

Methods

This study consecutively enrolled patients with MM who had a bortezomib-based induction regimen prior to ASCT. A total of one hundred twelve patients who achieved at least a partial response at two months post-autologous stem cell transplantation were studied [median age: 59 (30–74) years; male/female ratio: 60/52].

Results

Twenty-five patients did not undergo any consolidation, whereas eighty-seven patients got a median of 2 cycles (range: 1–6) of cyclophosphamide-bortezomib-dexamethasone (CyBorD) for Bortezomib-Lenalidomide-Dexamethasone (VRD) consolidation following ASCT. Progression-free survival (PFS) in the overall trial cohort was longer in patients receiving consolidation therapy (57 months versus 44 months, p = 0.06). Among patients exhibiting a very good partial response (VGPR) or partial response (PR) to ASCT, PFS was markedly prolonged in those who underwent consolidation cycles compared to those who did not (57 vs. 12 months; p = 0.04). Conversely, in the stringent complete remission (sCR) or complete remission (CR) cohort, PFS did not differ between patients who received consolidation cycles and those who did not. The analysis revealed no statistically significant differences in overall survival (OS) between the two answer category groups (p > 0.05). The PFS (p > 0.05) and incidence of severe toxicity (p > 0.05) were comparable for patients receiving CyBorD and VRD consolidation regimens.

Conclusions

Our study demonstrated that consolidation therapy is safe regarding its adverse effect profile, and that its beneficial impact on PFS in first-line treatment is particularly evident in patients exhibiting VGPR and PR to ASCT.